INTRAPERITONEAL AND SUBCUTANEOUS XENOGRAFTS OF HUMAN OVARIAN-CARCINOMA IN NUDE-MICE AND THEIR POTENTIAL IN EXPERIMENTAL-THERAPY
INTRAPERITONEAL AND SUBCUTANEOUS XENOGRAFTS OF HUMAN OVARIAN-CARCINOMA IN NUDE-MICE AND THEIR POTENTIAL IN EXPERIMENTAL-THERAPY
复制标题
DOI：
10.1002/ijc.2910440320
复制
发表时间：
1989-09-15
影响因子：
6.4
通讯作者：
GIAVAZZI, R
中科院分区：
文献类型：
--
作者：
MASSAZZA, G;TOMASONI, A;GIAVAZZI, R
人卵巢癌（HOC）是通过皮下注射建立的。并对4种移植瘤的生物学特性进行了研究。分别来源于卵巢的原发性肿瘤和胸腔积液（来自2个不同的患者）的HOC8和HOC18被皮下建立。在裸鼠中。HOC10和HOC22来源于2名患者的腹水，在裸鼠中腹膜内注射后直接建立为腹水。南卡罗来纳并研究了4种HOC细胞系的i.p.生长行为。HOC18、HOC8和HOC22细胞在s.c.注射，但HOC10腹水不会在s.c.源自HOC18的细胞悬浮液在腹膜内注射后仅产生癌病，而HOC8细胞产生腹水和癌病。2个腹水HOC10和HOC22在裸鼠中产生腹水，但只有HOC22形成腹膜内癌病。无论肿瘤植入部位如何，患者原发性肿瘤的组织学特征在裸鼠中持续存在。异种移植物的DNA直方图与患者的肿瘤密切匹配，并且在不同的传代中保持稳定。测试静脉内给予的顺铂、阿霉素和环磷酰胺对皮下生长的HOC8和HOC18的抑制作用。HOC22和HOC10对DDP有明显的敏感性，而对阿霉素和环磷酰胺几乎不敏感。HOC18在所有3种药物下仅显示中度生长延迟。荷HOC 10和HOC 22腹水的小鼠经DDP和ADR治疗后生存时间延长。
Human ovarian carcinomas (HOC) were established s.c. and i.p. in nude mice and the biological characteristics were investigated for 4 xenografts. HOC8 and HOC18, derived respectively from a primary tumor of the ovary and a pleural effusion (from 2 different patients) were established s.c. in nude mice. HOC10 and HOC22, derived from the ascites of 2 patients, were directly established as ascites after i.p. injection in nude mice. The s.c. and i.p. growth behavior of the 4 HOC lines was investigated. HOC18, HOC8 and HOC22 cells produced progressively growing tumor after s.c. injection but HOC10 ascites would not grow s.c. The cell suspension derived from HOC18 only produced carcinomatosis upon i.p. injection, while HOC8 cells produced both ascites and carcinomatosis. The 2 ascites HOC10 and HOC22 produced ascites in nude mice, but only HOC22 formed i.p. carcinomatosis. Histopathological characteristics of the patients'' primary tumors persisted in nude mice, regardless of the site of tumor implantation. DNA histograms of the xenografts closely matched the patients'' tumors and remained stable at different passages. Cisplatin, adriamycin and cyclophosphamide given i.v. were tested against HOC8 and HOC18 growing s.c. and HOC22 and HOC10 growing i.p. HOC8 showed a significant response to DDP and almost no sensitivity to ADR and CTX. HOC18 showed only moderate growth delay with all 3 drugs. Mice bearing HOC10 and HOC22 ascites had a prolonged survival time after DDP and ADR treatment.